Rheumatoid arthritis drug reduces risk of death for severely ill hospitalized Covid-19 patients, researchers say

▴ Rheumatoid arthritis drug reduces risk of death for severely ill hospitalized Covid-19 patients, researchers say
The treatment reduces mortality, shortens hospital stay and reduces the chances of people needing invasive mechanical ventilators

Tocilizumab, an intravenous anti-inflammatory drug used for rheumatoid arthritis, has been shown to reduce the risk of death for patients hospitalized with severe Covid-19, as well as reducing the risk of ventilation and the amount of time until discharged from hospital.

The preliminary results came from the RECOVERY trial, which has been testing potential Covid-19 treatments since March 2020. Tocilizumab was added to the trial in April 2020. The results were shared in a preprint, but have not yet been peer-reviewed or published in a medical journal.

For the trial, 2,022 patients were randomly allocated tocilizumab and compared with 2,094 patients who received standard care.

"There were 596 deaths amongst the people in the tocilizumab group, 29%, and there were 694 deaths, 33%, in the usual care group. So that is a reduction in the risk of deaths of around about a sixth or a seventh," Martin Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health at the University of Oxford, and deputy chief investigator of the RECOVERY trial, said during a briefing on Thursday.

"An absolute difference of four in a hundred," Landray said. "You need to treat about 25 patients in order to save one patient, one life."

Landray said that the benefits were consistent in every group of patients studied.

The drug was also shown to have a benefit for people who were not on mechanical ventilation at the start of the trial; the risk of progressing to mechanical ventilation or death reducing from 38% to 33%. The treatment's benefits were in addition to those from steroids such as dexamethasone -- 82% of patients were receiving one of these steroids.

"The data suggest that in Covid-19 patients with hypoxia (requiring oxygen) and significant inflammation, treatment with the combination of systemic corticosteroid (such as dexamethasone) plus tocilizumab reduces mortality by about one third for patients requiring simple oxygen and nearly one half for those requiring invasive mechanical ventilation," said a press release from the University of Oxford.

"This is a treatment, just in summary, that reduces mortality, shortens hospital stay and reduces the chances of people needing invasive mechanical ventilators," Landray said. "That's good for patients, that's good for the health service. And that's good not only for the health service and patients here in the UK, but internationally."

On February 3, a National Institutes of Health panel released treatment guidelines that say for patients in the intensive care unit, "there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of Covid-19." Sarilumab is a similar treatment for rheumatoid arthritis. For those not requiring ICU-level care, the panel recommended against the use of the drugs except for in a clinical trial.

Landray noted that many of the earlier trials were smaller, and the results weren't clear.

"Until these results from RECOVERY, it has been inconclusive," he said, even in other large trials, such as REMAP-CAP. When the results of RECOVERY are added on top of others, "it becomes completely clear cut."
The National Health Service has large numbers of patients who have been able to contribute to the trials, "that's how you get really clear answers and then you get certainty where there was none before."

Tags : #RheumatoidArthritisDrug #LatestPharmaResearch12thFeb #UniversityofOxford #LatestMedicineforCOVID #LatestPharmaNews12thFeb #NationalHealthService #LatestTreatmentforCOVID

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023